Compare VANI & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VANI | BGX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 135.2M |
| IPO Year | 2014 | 2010 |
| Metric | VANI | BGX |
|---|---|---|
| Price | $1.44 | $10.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 300.2K | 59.2K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $10.38 |
| 52 Week High | $1.92 | $12.60 |
| Indicator | VANI | BGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 51.24 |
| Support Level | $1.24 | $10.76 |
| Resistance Level | $1.55 | $10.93 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 51.00 | 72.73 |
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.